Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant

NCT06839456 is registered in ClinicalTrials.gov with Children's Hospital of Philadelphia as lead sponsor.

NCT NCT06839456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06839456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant
Lead sponsor
Children's Hospital of Philadelphia
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 21, 2025
Completion date
March 31, 2032
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acquired aplastic anemia, bone marrow failure, hemoglobinopathies, high risk acute lymphoblastic leukemia, high risk acute myeloid leukemia, hlh, immunodeficiency, inborn errors of metabolism, inherited bmf syndrome, leukemia, mds (myelodysplastic syndrome), primary immune regulatory disorder, relapse leukemia, relapsed non-hodgkin lymphoma